TERT promoter mutations in cancer development.
(2014) In Current Opinion in Genetics & Development 24(Dec 20). p.30-37- Abstract
- Human telomerase reverse transcriptase (TERT) encodes a rate-limiting catalytic subunit of telomerase that maintains genomic integrity. TERT expression is mostly repressed in somatic cells with exception of proliferative cells in self-renewing tissues and cancer. Immortality associated with cancer cells has been attributed to telomerase over-expression. The precise mechanism behind the TERT activation in cancers has mostly remained unknown. The newly described germline and recurrent somatic mutations in melanoma and other cancers in the TERT promoter that create de novo E-twenty six/ternary complex factors (Ets/TCF) binding sites, provide an insight into the possible cause of tumor-specific increased TERT expression. In this review we... (More)
- Human telomerase reverse transcriptase (TERT) encodes a rate-limiting catalytic subunit of telomerase that maintains genomic integrity. TERT expression is mostly repressed in somatic cells with exception of proliferative cells in self-renewing tissues and cancer. Immortality associated with cancer cells has been attributed to telomerase over-expression. The precise mechanism behind the TERT activation in cancers has mostly remained unknown. The newly described germline and recurrent somatic mutations in melanoma and other cancers in the TERT promoter that create de novo E-twenty six/ternary complex factors (Ets/TCF) binding sites, provide an insight into the possible cause of tumor-specific increased TERT expression. In this review we discuss the discovery and possible implications of the TERT promoter mutations in melanoma and other cancers. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4379907
- author
- Heidenreich, Barbara ; Rachakonda, P Sivaramakrishna ; Hemminki, Kari LU and Kumar, Rajiv
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Current Opinion in Genetics & Development
- volume
- 24
- issue
- Dec 20
- pages
- 30 - 37
- publisher
- Elsevier
- external identifiers
-
- pmid:24657534
- wos:000335806900006
- scopus:84890636883
- pmid:24657534
- ISSN
- 1879-0380
- DOI
- 10.1016/j.gde.2013.11.005
- language
- English
- LU publication?
- yes
- id
- 61594a76-2486-4d75-aff1-e66dff6a1102 (old id 4379907)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24657534?dopt=Abstract
- date added to LUP
- 2016-04-01 10:32:46
- date last changed
- 2022-03-04 20:37:39
@article{61594a76-2486-4d75-aff1-e66dff6a1102,
abstract = {{Human telomerase reverse transcriptase (TERT) encodes a rate-limiting catalytic subunit of telomerase that maintains genomic integrity. TERT expression is mostly repressed in somatic cells with exception of proliferative cells in self-renewing tissues and cancer. Immortality associated with cancer cells has been attributed to telomerase over-expression. The precise mechanism behind the TERT activation in cancers has mostly remained unknown. The newly described germline and recurrent somatic mutations in melanoma and other cancers in the TERT promoter that create de novo E-twenty six/ternary complex factors (Ets/TCF) binding sites, provide an insight into the possible cause of tumor-specific increased TERT expression. In this review we discuss the discovery and possible implications of the TERT promoter mutations in melanoma and other cancers.}},
author = {{Heidenreich, Barbara and Rachakonda, P Sivaramakrishna and Hemminki, Kari and Kumar, Rajiv}},
issn = {{1879-0380}},
language = {{eng}},
number = {{Dec 20}},
pages = {{30--37}},
publisher = {{Elsevier}},
series = {{Current Opinion in Genetics & Development}},
title = {{TERT promoter mutations in cancer development.}},
url = {{http://dx.doi.org/10.1016/j.gde.2013.11.005}},
doi = {{10.1016/j.gde.2013.11.005}},
volume = {{24}},
year = {{2014}},
}